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Corrections for Fig. 2, Fig. 3, and Fig. 4 in page 340 are needed.

There were some mistakes in the numerical values of the graphs. We apologize for any inconvenience that this may have caused.

• Before correction

**Fig. 2.** P1NP levels before and 1 month after administrating the anti-RANKL antibody. P1NP, N-terminal propeptide of type 1 collagen; RANKL, receptor activator of nuclear factor-kappa B ligand; NS, not significant.

• After correction

**Fig. 2.** P1NP levels before and 1 month after administrating the anti-RANKL antibody. P1NP, N-terminal propeptide of type 1 collagen; RANKL, receptor activator of nuclear factor-kappa B ligand; NS, not significant.
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**Fig. 3.** The averages YAM level for the anti-RANKL antibody before and 6 months after treatment. YAM, young adult mean; RANKL, receptor activator of nuclear factor-kappa B ligand.
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**Fig. 3.** The averages YAM level for the anti-RANKL antibody before and 6 months after treatment. YAM, young adult mean; RANKL, receptor activator of nuclear factor-kappa B ligand.
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**Fig. 4.** The time course changes by using the back pain VAS before treatment and 1, 2, 3, and 6 months after treatment. VAS, visual analogue scale; NS, not significant.
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**Fig. 4.** The time course changes by using the back pain VAS before treatment and 1, 2, 3, and 6 months after treatment. VAS, visual analogue scale; NS, not significant.
